Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | CCNC | P24863 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 7/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7988012 | 0.86 | CYP2A6 (0.45) | HSD11B1PIK3CBCYP2A6 | |
| SCHEMBL23187978 | 0.82 | CYP11B2 (0.64) | HSD11B1CCNCCDK8FAAHCYP2A6 | |
| SCHEMBL3348340 | 0.81 | PRKCI (0.56) | HSD11B1PRKCILRRK2CCNCCDK8 | |
| SCHEMBL18029323 | 0.81 | HSD11B1 (0.53) | HSD11B1PRKCILRRK2CCNCCDK8 | |
| Hydrochloric Acid SCHEMBL14909693 | 0.80 | PRKCI (0.54) | HSD11B1PRKCILRRK2CCNCCDK8 | |
| SCHEMBL14923422 | 0.77 | FAAH (0.47) | HSD11B1PRKCILRRK2CCNCCDK8 | |
| SCHEMBL19662764 | 0.77 | LRRK2 (0.70) | HSD11B1PRKCILRRK2FAAHPIK3CB | |
| SCHEMBL13786855 | 0.77 | HSD11B1 (0.55) | HSD11B1PRKCILRRK2FAAHCYP2A6 | |
| SCHEMBL30241674 | 0.77 | HSD11B1 (0.69) | HSD11B1PRKCILRRK2FAAHCYP2A6 | |
| SCHEMBL5256926 | 0.77 | HSD11B1 (0.69) | HSD11B1PRKCILRRK2FAAHCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109153643-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2022-06-21 | — | — | CN | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| EP-3423435-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | HSD11B1 4071/4885PRKCI 444/4885LRRK2 52/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | HSD11B1 4071/4885PRKCI 444/4885LRRK2 52/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | HSD11B1 4071/4885PRKCI 444/4885LRRK2 52/4885 |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | HSD11B1 4071/4885PRKCI 444/4885LRRK2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.